Stockreport

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF antibody OX40 antagonist, allowing the company to proceed with a Phase 1a trial in healthy subjects in the first quarter of 2025. Astria Therapeutics is a biopharmaceu [Read more]